{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:04:06Z","timestamp":1779883446452,"version":"3.53.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["270650915\/GRK 2158"],"award-info":[{"award-number":["270650915\/GRK 2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["270650915\/GRK 2158"],"award-info":[{"award-number":["270650915\/GRK 2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cyclin-dependent kinases (CDKs) play a crucial role in cell cycle (such as CDK1 and CDK4\/6) and transcription (such as CDK7, CDK9, and CDK12\/13). While CDK inhibitors are clinically effective in cancer therapy, their mechanisms of apoptosis induction remain incompletely understood. Here, we demonstrate that inhibition of CDKs involved in cell cycle control (such as CDK1 or CDK4\/6) displays no cytotoxic potential. Surprisingly, inhibition of CDK7, which is involved in the control of cell cycle and transcriptional initiation, also showed no cytotoxicity. Only inhibition of CDK9 (by AZD4573 and atuveciclib) or of CDK12\/13 (by SR4835 and THZ531)\u2013which target the transcriptional elongation of RNA polymerase II (RNAPII)\u2013exerted a strong apoptotic potential. Since CDK9 and CDK12\/13 target different elongation factors associated with RNAPII (such as SPT6 and NELF for CDK9; CDC73, and LEO1 for CDK12\/13), they cannot substitute for each other. Consequently, the combination of AZD4573 with SR4835 resulted in significant, synergistic cytotoxicity. Inhibiting CDK9 or CDK12\/13 induced the rapid downregulation of the short-lived, anti-apoptotic Bcl-2 proteins Mcl1 and A1\/Bfl1 in Jurkat leukemia cells and SUDHL1 lymphoma cells, whereas the expression of Bcl-2 and Bcl-xL remained unaffected. Since Mcl1 and A1 antagonize the pro-apoptotic Bcl-2 proteins Bak and Bax, apoptosis induction by AZD4573 or SR4835 was blocked in Bak- and Bax\/Bak-deficient Jurkat cells and strongly reduced in Bax-deficient cells. Because Bcl-2 only inhibits Bax, but not Bak, AZD4573 and SR4835 were able to induce apoptosis in Jurkat cells overexpressing Bcl-2. As tumor cells frequently upregulate Bcl-2, inhibitors of CDK9 and CDK12\/13 represent promising anticancer drugs.<\/jats:p>","DOI":"10.1038\/s41419-026-08889-6","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:37:02Z","timestamp":1779874622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of RNA polymerase II-activating CDK9 and CDK12\/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1\/A1"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-1395","authenticated-orcid":false,"given":"Karina S.","family":"Krings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7466-5431","authenticated-orcid":false,"given":"Judith","family":"Hatzfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya R.","family":"Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0020-9800","authenticated-orcid":false,"given":"Laura","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri M.","family":"Itkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-2279","authenticated-orcid":false,"given":"Christoph","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-7806","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Stork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Geyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Klebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8043","authenticated-orcid":false,"given":"Nan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-942X","authenticated-orcid":false,"given":"Sebastian","family":"Wesselborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"8889_CR1","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/ijms22062935","volume":"22","author":"P Lukasik","year":"2021","unstructured":"Lukasik P, Zaluski M, Gutowska I. Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review. Int J Mol Sci. 2021;22:2935.","journal-title":"Int J Mol Sci"},{"key":"8889_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/13543784.2022.2097067","volume":"31","author":"X Guo","year":"2022","unstructured":"Guo X, Chen H, Zhou Y, Shen L, Wu S, Chen Y. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4\/6 inhibition. Expert Opin Investig Drugs. 2022;31:933\u201344.","journal-title":"Expert Opin Investig Drugs"},{"key":"8889_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2021","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2021;23:74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8889_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41416-024-02589-8","volume":"130","author":"X Song","year":"2024","unstructured":"Song X, Fang C, Dai Y, Sun Y, Qiu C, Lin X, et al. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. Br J Cancer. 2024;130:1239\u201348.","journal-title":"Br J Cancer"},{"key":"8889_CR5","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41388-022-02347-1","volume":"41","author":"TA Constantin","year":"2022","unstructured":"Constantin TA, Greenland KK, Varela-Carver A, Bevan CL. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene. 2022;41:3303\u201315.","journal-title":"Oncogene"},{"key":"8889_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle S, Amat R, Glover-Cutter K, Sans\u00f3 M, Zhang C, Allen JJ, et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol. 2012;19:1108\u201315.","journal-title":"Nat Struct Mol Biol"},{"key":"8889_CR7","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1093\/nar\/gkaa514","volume":"48","author":"M Tellier","year":"2020","unstructured":"Tellier M, Zaborowska J, Caizzi L, Mohammad E, Velychko T, Schwalb B, et al. CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation. Nucleic Acids Res. 2020;48:7712\u201327.","journal-title":"Nucleic Acids Res"},{"key":"8889_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1101\/gad.335679.119","volume":"34","author":"AC Schier","year":"2020","unstructured":"Schier AC, Taatjes DJ. Structure and mechanism of the RNA polymerase II transcription machinery. Genes Dev. 2020;34:465\u201388.","journal-title":"Genes Dev"},{"key":"8889_CR9","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1016\/j.molcel.2023.10.004","volume":"83","author":"Y Aoi","year":"2023","unstructured":"Aoi Y, Shilatifard A. Transcriptional elongation control in developmental gene expression, aging, and disease. Mol Cell. 2023;83:3972\u201399.","journal-title":"Mol Cell"},{"key":"8889_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molcel.2005.11.024","volume":"21","author":"T Yamada","year":"2006","unstructured":"Yamada T, Yamaguchi Y, Inukai N, Okamoto S, Mura T, Handa H. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol Cell. 2006;21:227\u201337.","journal-title":"Mol Cell"},{"key":"8889_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-018-0440-4","volume":"560","author":"SM Vos","year":"2018","unstructured":"Vos SM, Farnung L, Boehning M, Wigge C, Linden A, Urlaub H, et al. Structure of activated transcription complex Pol II\u2013DSIF\u2013PAF\u2013SPT6. Nature. 2018;560:607\u201312.","journal-title":"Nature"},{"key":"8889_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf8698","volume":"9","author":"M Qiu","year":"2023","unstructured":"Qiu M, Yin Z, Wang H, Lei L, Li C, Cui Y, et al. CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation. Sci Adv. 2023;9:eadf8698.","journal-title":"Sci Adv"},{"key":"8889_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1126\/science.aad2338","volume":"350","author":"M Yu","year":"2015","unstructured":"Yu M, Yang W, Ni T, Tang Z, Nakadai T, Zhu J, et al. RNA polymerase II\u2013associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science. 2015;350:1383\u20136.","journal-title":"Science"},{"key":"8889_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/21541264.2018.1539615","volume":"10","author":"MD Galbraith","year":"2019","unstructured":"Galbraith MD, Bender H, Espinosa JM. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2019;10:118\u201336.","journal-title":"Transcription"},{"key":"8889_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang Q, Bode AM, Zhang T. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 2023;7:58.","journal-title":"NPJ Precis Oncol"},{"key":"8889_CR16","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11:1913.","journal-title":"Am J Cancer Res"},{"key":"8889_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4155\/fmc-2020-0240","volume":"13","author":"S Tadesse","year":"2021","unstructured":"Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12\/13 inhibition for the treatment of cancer. Future Med Chem. 2021;13:117\u201341.","journal-title":"Future Med Chem"},{"key":"8889_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10:351\u201370.","journal-title":"Cancer Discov"},{"key":"8889_CR19","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam B, Casella R, Cidado J, Cook C, De Savi C, Dishington A, et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J Med Chem. 2020;63:15564\u201390.","journal-title":"J Med Chem"},{"key":"8889_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"8889_CR21","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1182\/blood.2020008528","volume":"137","author":"S Boiko","year":"2021","unstructured":"Boiko S, Proia T, San Martin M, Gregory GP, Wu MM, Aryal N, et al. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood. 2021;137:2947\u201357.","journal-title":"Blood"},{"key":"8889_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1158\/0008-5472.CAN-05-1769","volume":"66","author":"D Cai","year":"2006","unstructured":"Cai D, Byth KF, Shapiro GI. AZ703, an imidazo [1, 2-a] pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res. 2006;66:435\u201344.","journal-title":"Cancer Res"},{"key":"8889_CR23","doi-asserted-by":"publisher","first-page":"9270","DOI":"10.1158\/0008-5472.CAN-06-1758","volume":"66","author":"D Cai","year":"2006","unstructured":"Cai D, Latham JrVM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 2006;66:9270\u201380.","journal-title":"Cancer Res"},{"key":"8889_CR24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00535-009-0111-1","volume":"44","author":"L-C Chou","year":"2009","unstructured":"Chou L-C, Yang J-S, Huang L-J, Wu H-C, Lu C-C, Chiang J-H, et al. The synthesized 2-(2-fluorophenyl)-6, 7-methylenedioxyquinolin-4-one (CHM-1) promoted G2\/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. J Gastroenterol. 2009;44:1055\u201363.","journal-title":"J Gastroenterol"},{"key":"8889_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bcp.2011.10.008","volume":"83","author":"R Chu","year":"2012","unstructured":"Chu R, Terrano DT, Chambers TC. Cdk1\/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem Pharmacol. 2012;83:199\u2013206.","journal-title":"Biochem Pharmacol"},{"key":"8889_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4161\/cc.1.2.116","volume":"1","author":"Y Dai","year":"2002","unstructured":"Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor. Cell Cycle. 2002;1:128\u201337.","journal-title":"Cell Cycle"},{"key":"8889_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2015.66","volume":"2","author":"J Megyesi","year":"2016","unstructured":"Megyesi J, Tarcsafalvi A, Seng NHL, Hodeify R, Price P. Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax\/Bak. Cell Death Discov. 2016;2:1\u20139.","journal-title":"Cell Death Discov"},{"key":"8889_CR28","doi-asserted-by":"publisher","first-page":"e12341","DOI":"10.1371\/journal.pone.0012341","volume":"5","author":"D Nantajit","year":"2010","unstructured":"Nantajit D, Fan M, Duru N, Wen Y, Reed JC, Li JJ. Cyclin B1\/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS One. 2010;5:e12341.","journal-title":"PLoS One"},{"key":"8889_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","volume":"443","author":"B Xie","year":"2019","unstructured":"Xie B, Wang S, Jiang N, Li JJ. Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett. 2019;443:56\u201366.","journal-title":"Cancer Lett"},{"key":"8889_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-017-0356-x","volume":"10","author":"R Zhang","year":"2017","unstructured":"Zhang R, Shi H, Ren F, Zhang M, Ji P, Wang W, et al. The aberrant upstream pathway regulations of CDK1 protein were implicated in the proliferation and apoptosis of ovarian cancer cells. J Ovarian Res. 2017;10:1\u201311.","journal-title":"J Ovarian Res"},{"key":"8889_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.18388\/abp.2009_2485","volume":"56","author":"J Wesierska-Gadek","year":"2009","unstructured":"Wesierska-Gadek J, Borza A, Komina O, Maurer M. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Acta Biochim Pol. 2009;56:495\u2013501.","journal-title":"Acta Biochim Pol"},{"key":"8889_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2174\/138161211795049714","volume":"17","author":"J Wesierska-Gadek","year":"2011","unstructured":"Wesierska-Gadek J, Maurer M. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms. Curr Pharm Des. 2011;17:256\u201371.","journal-title":"Curr Pharm Des"},{"key":"8889_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36:545\u201358.e7.","journal-title":"Cancer Cell"},{"key":"8889_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016;12:876\u201384.","journal-title":"Nat Chem Biol"},{"key":"8889_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019;10:1757.","journal-title":"Nat Commun"},{"key":"8889_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41420-024-02056-6","volume":"10","author":"L Schmitt","year":"2024","unstructured":"Schmitt L, Hoppe J, Cea-Medina P, Bruch P-M, Krings KS, Lechtenberg I, et al. Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs). Cell Death Discov. 2024;10:279.","journal-title":"Cell Death Discov"},{"key":"8889_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41420-024-01901-y","volume":"10","author":"L Schmitt","year":"2024","unstructured":"Schmitt L, Lechtenberg I, Drie\u00dfen D, Flores-Romero H, Skowron MA, Sekeres M, et al. Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2. Cell Death Discov. 2024;10:125.","journal-title":"Cell Death Discov"},{"key":"8889_CR38","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","volume":"113","author":"R Chen","year":"2009","unstructured":"Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009;113:4637\u201345.","journal-title":"Blood"},{"key":"8889_CR39","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1158\/0008-5472.CAN-09-0301","volume":"69","author":"S Ali","year":"2009","unstructured":"Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009;69:6208\u201315.","journal-title":"Cancer Res"},{"key":"8889_CR40","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1038\/cddis.2011.66","volume":"2","author":"G Polier","year":"2011","unstructured":"Polier G, Ding J, Konkimalla B, Eick D, Ribeiro N, K\u00f6hler R, et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2011;2:e182\u2013e.","journal-title":"Cell Death Dis"},{"key":"8889_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1097-2765(04)00156-X","volume":"14","author":"X-M Sun","year":"2004","unstructured":"Sun X-M, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. Caspase activation inhibits proteasome function during apoptosis. Mol Cell. 2004;14:81\u201393.","journal-title":"Mol Cell"},{"key":"8889_CR42","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1535-7163.MCT-16-0031","volume":"15","author":"RS Soderquist","year":"2016","unstructured":"Soderquist RS, Eastman A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Ther. 2016;15:2011\u20137.","journal-title":"Mol Cancer Ther"},{"key":"8889_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8889_CR44","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature06046","volume":"448","author":"D Santamar\u00eda","year":"2007","unstructured":"Santamar\u00eda D, Barri\u00e8re C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811\u20135.","journal-title":"Nature"},{"key":"8889_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020;39:805\u201323.","journal-title":"Cancer Metastasis Rev"},{"key":"8889_CR46","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159:1126\u201339.","journal-title":"Cell"},{"key":"8889_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SH, et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol Cancer Ther. 2018;17:1156\u201366.","journal-title":"Mol Cancer Ther"},{"key":"8889_CR48","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 2019;79:3479\u201391.","journal-title":"Cancer Res"},{"key":"8889_CR49","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/MCB.00595-14","volume":"34","author":"TW Kelso","year":"2014","unstructured":"Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014;34:3675\u201388.","journal-title":"Mol Cell Biol"},{"key":"8889_CR50","doi-asserted-by":"crossref","unstructured":"Wang B-Y, Liu Q-Y, Cao J, Chen J-W, Liu Z-S. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 20;10:1181\u20139","DOI":"10.2147\/DDDT.S86317"},{"key":"8889_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","volume":"26","author":"CL Christensen","year":"2014","unstructured":"Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014;26:909\u201322.","journal-title":"Cancer Cell"},{"key":"8889_CR52","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616\u201320.","journal-title":"Nature"},{"key":"8889_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43760-z","volume":"9","author":"YJ Choi","year":"2019","unstructured":"Choi YJ, Kim DH, Yoon DH, Suh C, Choi C-M, Lee JC, et al. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. Sci Rep. 2019;9:7193.","journal-title":"Sci Rep"},{"key":"8889_CR54","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/emboj.2012.94","volume":"31","author":"M Ganuza","year":"2012","unstructured":"Ganuza M, S\u00e1iz-Ladera C, Ca\u00f1amero M, G\u00f3mez G, Schneider R, Blasco MA, et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 2012;31:2498\u2013510.","journal-title":"EMBO J"},{"key":"8889_CR55","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol. 2019;26:792\u2013803.e10.","journal-title":"Cell Chem Biol"},{"key":"8889_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell. 2020;37:37\u201354.e9.","journal-title":"Cancer Cell"},{"key":"8889_CR57","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.molcel.2025.04.012","volume":"85","author":"D Lopez Martinez","year":"2025","unstructured":"Lopez Martinez D, Todorovski I, Gonzalez MN, Rusimbi C, Blears D, Khallou N, et al. PAF1C-mediated activation of CDK12\/13 kinase activity is critical for CTD phosphorylation and transcript elongation. Mol Cell. 2025;85:1952\u201367.e8.","journal-title":"Mol Cell"},{"key":"8889_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/cdd.2013.179","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 2014;21:491\u2013502.","journal-title":"Cell Death Differ"},{"key":"8889_CR59","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/aps.2016.49","volume":"37","author":"S Xie","year":"2016","unstructured":"Xie S, Jiang H, Zhai X-W, Wei F, Wang S-D, Ding J, et al. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin. 2016;37:1481\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"8889_CR60","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1182\/blood.V90.11.4307","volume":"90","author":"A K\u00f6nig","year":"1997","unstructured":"K\u00f6nig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood. 1997;90:4307\u201312.","journal-title":"Blood"},{"key":"8889_CR61","doi-asserted-by":"publisher","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","volume":"59","author":"YA Sonawane","year":"2016","unstructured":"Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy: miniperspective. J Med Chem. 2016;59:8667\u201384.","journal-title":"J Med Chem"},{"key":"8889_CR62","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770\u201383.","journal-title":"J Clin Oncol"},{"key":"8889_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543784.2013.789859","volume":"22","author":"P Bose","year":"2013","unstructured":"Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22:723\u201338.","journal-title":"Expert Opin Investig Drugs"},{"key":"8889_CR64","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1021\/np980530x","volume":"62","author":"BK Joshi","year":"1999","unstructured":"Joshi BK, Gloer JB, Wicklow DT. New verticillin and glisoprenin analogues from Gliocladium catenulatum, a mycoparasite of Aspergillus flavus sclerotia. J Nat Prod. 1999;62:730\u20133.","journal-title":"J Nat Prod"},{"key":"8889_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04050-7","volume":"12","author":"V Juric","year":"2021","unstructured":"Juric V, Hudson L, Fay J, Richards CE, Jahns H, Verreault M, et al. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death Dis. 2021;12:763.","journal-title":"Cell Death Dis"},{"key":"8889_CR66","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","volume":"106","author":"R Chen","year":"2005","unstructured":"Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005;106:2513\u20139.","journal-title":"Blood"},{"key":"8889_CR67","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1158\/0008-5472.CAN-07-1826","volume":"67","author":"K Bettayeb","year":"2007","unstructured":"Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, et al. Meriolins, a new class of cell death\u2013inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 2007;67:8325\u201334.","journal-title":"Cancer Res"},{"key":"8889_CR68","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1101\/gad.244368.114","volume":"28","author":"C-H Huang","year":"2014","unstructured":"Huang C-H, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014;28:1800\u201314.","journal-title":"Genes Dev"},{"key":"8889_CR69","doi-asserted-by":"publisher","first-page":"13663","DOI":"10.1074\/jbc.M600266200","volume":"281","author":"MJ Herold","year":"2006","unstructured":"Herold MJ, Zeitz J, Pelzer C, Kraus C, Peters A, Wohlleben G, et al. The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem. 2006;281:13663\u201371.","journal-title":"J Biol Chem"},{"key":"8889_CR70","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41418-018-0169-5","volume":"26","author":"L Lionnard","year":"2019","unstructured":"Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2019;26:902\u201317.","journal-title":"Cell Death Differ"},{"key":"8889_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11373-005-9064-4","volume":"13","author":"H-F Yang-Yen","year":"2006","unstructured":"Yang-Yen H-F. Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci. 2006;13:201\u20134.","journal-title":"J Biomed Sci"},{"key":"8889_CR72","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1074\/jbc.M610643200","volume":"282","author":"KW Adams","year":"2007","unstructured":"Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem. 2007;282:6192\u2013200.","journal-title":"J Biol Chem"},{"key":"8889_CR73","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cells3020418","volume":"3","author":"B Mojsa","year":"2014","unstructured":"Mojsa B, Lassot I, Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells. 2014;3:418\u201337.","journal-title":"Cells"},{"key":"8889_CR74","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1128\/MCB.01266-09","volume":"30","author":"DP Stewart","year":"2010","unstructured":"Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol. 2010;30:3099\u2013110.","journal-title":"Mol Cell Biol"},{"key":"8889_CR75","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1016\/j.cell.2025.07.034","volume":"188","author":"NW Harper","year":"2025","unstructured":"Harper NW, Birdsall GA, Honeywell ME, Ward KM, Pai AA, Lee MJ. RNA Pol II inhibition activates cell death independently from the loss of transcription. Cell. 2025;188:6301\u201316.","journal-title":"Cell"},{"key":"8889_CR76","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","volume":"76","author":"A Baker","year":"2016","unstructured":"Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, et al. The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia. Cancer Res. 2016;76:1158\u201369.","journal-title":"Cancer Res"},{"key":"8889_CR77","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"8889_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"8889_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","volume":"198","author":"AW Hird","year":"2019","unstructured":"Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019;198:59\u201367.","journal-title":"Pharmacol Ther"},{"key":"8889_CR80","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJ, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403\u201313.","journal-title":"Blood"},{"key":"8889_CR81","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2010","unstructured":"Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115:3304\u201313.","journal-title":"Blood"},{"key":"8889_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/srep27696","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.","journal-title":"Sci Rep"},{"key":"8889_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005659","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Chen Y, Yu L, Yang L. Mechanisms of venetoclax resistance and solutions. Front Oncol. 2022;12:1005659.","journal-title":"Front Oncol"},{"key":"8889_CR84","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/sj.onc.1203401","volume":"19","author":"C Belka","year":"2000","unstructured":"Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, et al. Differential role of caspase-8 and BID activation during radiation-and CD95-induced apoptosis. Oncogene. 2000;19:1181\u201390.","journal-title":"Oncogene"},{"key":"8889_CR85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"8889_CR86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271\u20139.","journal-title":"J Immunol Methods"},{"key":"8889_CR87","doi-asserted-by":"publisher","first-page":"9105","DOI":"10.1021\/acs.jmedchem.8b00049","volume":"61","author":"R Jorda","year":"2018","unstructured":"Jorda R, Hendrychov\u00e1 D, Voller J, R\u030cezni\u0301c\u030ckova\u0301 E, Gucky\u0301 T, Krystof V. How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases?. J Med Chem. 2018;61:9105\u201320.","journal-title":"J Med Chem"},{"key":"8889_CR88","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cmdc.201700447","volume":"12","author":"U L\u00fccking","year":"2017","unstructured":"L\u00fccking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, et al. Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer. ChemMedChem. 2017;12:1776\u201393.","journal-title":"ChemMedChem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08889-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:02:58Z","timestamp":1779879778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08889-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8889"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08889-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests. JE and BK are employees of Lead Discovery Center GmbH (LDC). LDC has licensed intellectual property (IP) covering CDK9 inhibitor atuveciclib to Bayer AG, which was later on sublicensed to Vincerx Pharma, Inc. In addition, LDC licensed additional chemistry IP for CDK7 inhibitors (e.g., LDC4297, leading to Q901 and QS1189) to Qurient Co. Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}